{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:19:53Z","timestamp":1780517993759,"version":"3.54.1"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-244x-13-214","type":"journal-article","created":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T12:14:57Z","timestamp":1377173697000},"source":"Crossref","is-referenced-by-count":34,"title":["Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)"],"prefix":"10.1186","volume":"13","author":[{"given":"Deanna L","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi J","family":"Wehring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber K","family":"Earl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli M","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith B","family":"Dickerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Warfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard A","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo-Cheol","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,22]]},"reference":[{"key":"1402_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1192\/bjp.124.5.413","volume":"124","author":"PJ Beumont","year":"1974","unstructured":"Beumont PJ, et al: The effects of phenothiazines on endocrine function: I. Patients with inappropriate lactation and amenorrhoea. J Psychiatry. 1974, 124: 413-419. 10.1192\/bjp.124.5.413.","journal-title":"J Psychiatry"},{"issue":"20","key":"1402_CR2","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","volume":"64","author":"PM Haddad","year":"2004","unstructured":"Haddad PM, Wieck A: Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004, 64 (20): 2291-2314. 10.2165\/00003495-200464200-00003.","journal-title":"Drugs"},{"key":"1402_CR3","first-page":"S248","volume":"8","author":"JSE Hellewell","year":"1998","unstructured":"Hellewell JSE, Cantillon M: Antipsychotic tolerability: the attitudes and perceptions of medical professionals, patients and caregivers towards the side effects of antipsychotic therapy. Eur Neuropsychopharmacol. 1998, 8: S248-","journal-title":"Eur Neuropsychopharmacol"},{"issue":"7","key":"1402_CR4","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1177\/0269881107078281","volume":"21","author":"C Bushe","year":"2007","unstructured":"Bushe C, Shaw M: Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol. 2007, 21 (7): 768-773.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"1402_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/schbul\/sbp116","volume":"36","author":"RW Buchanan","year":"2010","unstructured":"Buchanan RW, et al: The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010, 36 (1): 71-93. 10.1093\/schbul\/sbp116.","journal-title":"Schizophr Bull"},{"key":"1402_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1471-244X-12-83","volume":"12","author":"R Brugnoli","year":"2012","unstructured":"Brugnoli R, et al: Risk factors for suicide behaviors in the observational schizophrenia outpatient health outcomes (SOHO) study. BMC Psychiatry. 2012, 12: 83-10.1186\/1471-244X-12-83.","journal-title":"BMC Psychiatry"},{"issue":"4","key":"1402_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1056\/NEJM197801262980408","volume":"298","author":"AG Frantz","year":"1978","unstructured":"Frantz AG: Prolactin. N Engl J Med. 1978, 298 (4): 201-207. 10.1056\/NEJM197801262980408.","journal-title":"N Engl J Med"},{"issue":"1","key":"1402_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.schres.2012.11.005","volume":"143","author":"A Comparelli","year":"2013","unstructured":"Comparelli A, et al: Emotion recognition impairment is present early and is stable throughout the course of schizophrenia. Schizophr Res. 2013, 143 (1): 65-69. 10.1016\/j.schres.2012.11.005.","journal-title":"Schizophr Res"},{"key":"1402_CR9","first-page":"653","volume-title":"The biological principles of disease, in Endocrinology, S. LH and T. SO, Editors","author":"G Liddle","year":"1981","unstructured":"Liddle G, Liddle L: The biological principles of disease, in Endocrinology, S. LH and T. SO, Editors. 1981, Philadelphia, PA: Saunders, 653-754."},{"issue":"10","key":"1402_CR10","first-page":"851","volume":"11","author":"PA Marken","year":"1992","unstructured":"Marken PA, Haykal RF, Fisher JN: Management of psychotropic-induced hyperprolactinemia. Clin Pharm. 1992, 11 (10): 851-856.","journal-title":"Clin Pharm"},{"issue":"4","key":"1402_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1365-2265.1979.tb02093.x","volume":"10","author":"EA Lenton","year":"1979","unstructured":"Lenton EA, et al: Prolactin concentrations in normal menstrual cycles and conception cycles. Clin Endocrinol (Oxf). 1979, 10 (4): 383-391. 10.1111\/j.1365-2265.1979.tb02093.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"1402_CR12","doi-asserted-by":"publisher","first-page":"761","DOI":"10.4088\/JCP.v66n0614","volume":"66","author":"K Melkersson","year":"2005","unstructured":"Melkersson K: Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry. 2005, 66 (6): 761-767. 10.4088\/JCP.v66n0614.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1402_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3109\/02688699108998439","volume":"5","author":"JS Bevan","year":"1991","unstructured":"Bevan JS: Interpreting prolactin levels: implications for the management of large pituitary lesions. Br J Neurosurg. 1991, 5 (1): 3-6. 10.3109\/02688699108998439.","journal-title":"Br J Neurosurg"},{"issue":"3","key":"1402_CR14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.4088\/JCP.v68n0302","volume":"68","author":"OD Howes","year":"2007","unstructured":"Howes OD, et al: Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2007, 68 (3): 361-367. 10.4088\/JCP.v68n0302.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"1402_CR15","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.4088\/JCP.v67n0909","volume":"67","author":"DU Jung","year":"2006","unstructured":"Jung DU, et al: Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry. 2006, 67 (9): 1391-1396. 10.4088\/JCP.v67n0909.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"1402_CR16","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.psyneuen.2005.12.006","volume":"31","author":"BJ Kinon","year":"2006","unstructured":"Kinon BJ, et al: Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology. 2006, 31 (5): 577-588. 10.1016\/j.psyneuen.2005.12.006.","journal-title":"Psychoneuroendocrinology"},{"issue":"Suppl 2","key":"1402_CR17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0306-4530(02)00127-0","volume":"28","author":"BJ Kinon","year":"2003","unstructured":"Kinon BJ, et al: Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003, 28 (Suppl 2): 55-68.","journal-title":"Psychoneuroendocrinology"},{"issue":"6","key":"1402_CR18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/01.jcp.0000186738.84276.9f","volume":"25","author":"DU Jung","year":"2005","unstructured":"Jung DU, et al: The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia. J Clin Psychopharmacol. 2005, 25 (6): 613-615. 10.1097\/01.jcp.0000186738.84276.9f.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"1402_CR19","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","volume":"80","author":"ME Freeman","year":"2000","unstructured":"Freeman ME, et al: Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000, 80 (4): 1523-1631.","journal-title":"Physiol Rev"},{"issue":"1","key":"1402_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0306-4530(81)90044-5","volume":"6","author":"GA Gudelsky","year":"1981","unstructured":"Gudelsky GA: Tuberoinfundibular dopamine neurons and the regulation of prolactin secretion. Psychoneuroendocrinology. 1981, 6 (1): 3-16. 10.1016\/0306-4530(81)90044-5.","journal-title":"Psychoneuroendocrinology"},{"issue":"3","key":"1402_CR21","first-page":"249","volume":"37","author":"J Tuomisto","year":"1985","unstructured":"Tuomisto J, Mannisto P: Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev. 1985, 37 (3): 249-332.","journal-title":"Pharmacol Rev"},{"issue":"10","key":"1402_CR22","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1176\/ajp.144.10.1335","volume":"144","author":"NA Keks","year":"1987","unstructured":"Keks NA, Copolov DL, Singh BS: Abnormal prolactin response to haloperidol challenge in men with schizophrenia. Am J Psychiatry. 1987, 144 (10): 1335-1337.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1402_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/archpsyc.1976.01770030003001","volume":"33","author":"HY Meltzer","year":"1976","unstructured":"Meltzer HY, Fang VS: The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry. 1976, 33 (3): 279-286. 10.1001\/archpsyc.1976.01770030003001.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"1402_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/00004714-200204000-00002","volume":"22","author":"S Smith","year":"2002","unstructured":"Smith S, et al: The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol. 2002, 22 (2): 109-114. 10.1097\/00004714-200204000-00002.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"1402_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1176\/appi.ajp.159.1.133","volume":"159","author":"P Turrone","year":"2002","unstructured":"Turrone P, et al: Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry. 2002, 159 (1): 133-135. 10.1176\/appi.ajp.159.1.133.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"1402_CR26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/00004714-199710000-00010","volume":"17","author":"PV Tran","year":"1997","unstructured":"Tran PV, et al: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997, 17 (5): 407-418. 10.1097\/00004714-199710000-00010.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"1402_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0920-9964(97)00036-4","volume":"26","author":"AM Crawford","year":"1997","unstructured":"Crawford AM, Beasley CM, Tollefson GD: The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res. 1997, 26 (1): 41-54. 10.1016\/S0920-9964(97)00036-4.","journal-title":"Schizophr Res"},{"issue":"3","key":"1402_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s004060170049","volume":"251","author":"M Markianos","year":"2001","unstructured":"Markianos M, Hatzimanolis J, Lykouras L: Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. Eur Arch Psychiatry Clin Neurosci. 2001, 251 (3): 141-146. 10.1007\/s004060170049.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"4","key":"1402_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","volume":"42","author":"LA Arvanitis","year":"1997","unstructured":"Arvanitis LA, Miller BG: Multiple fixed doses of \u201cSeroquel\u201d (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry. 1997, 42 (4): 233-246. 10.1016\/S0006-3223(97)00190-X.","journal-title":"Biol Psychiatry"},{"issue":"6","key":"1402_CR30","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1001\/archpsyc.1997.01830180067009","volume":"54","author":"JG Small","year":"1997","unstructured":"Small JG, et al: Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel study group. Arch Gen Psychiatry. 1997, 54 (6): 549-557. 10.1001\/archpsyc.1997.01830180067009.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"1402_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s002130050603","volume":"137","author":"DJ King","year":"1998","unstructured":"King DJ, Link CG, Kowalcyk B: A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. Psychopharmacology (Berl). 1998, 137 (2): 139-146. 10.1007\/s002130050603.","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"1402_CR32","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/00004714-199604000-00008","volume":"16","author":"RL Borison","year":"1996","unstructured":"Borison RL, Arvanitis LA, Miller BG: ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. Seroquel. Study group. J Clin Psychopharmacol. 1996, 16 (2): 158-169. 10.1097\/00004714-199604000-00008.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"1402_CR33","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/schbul\/sbp037","volume":"37","author":"KP Grootens","year":"2011","unstructured":"Grootens KP, et al: Ziprasidone vs. olanzapine in recent onset schizophrenia and schizoaffective disorder: results of an 8-week double blind randomized controlled trial. Schizophr Bull. 2011, 37 (2): 352-361. 10.1093\/schbul\/sbp037.","journal-title":"Schizophr Bull"},{"issue":"3","key":"1402_CR34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3109\/10398561003686763","volume":"18","author":"M Skopek","year":"2010","unstructured":"Skopek M, Manoj P: Hyperprolactinaemia during treatment with paliperidone. Australas Psychiatry. 2010, 18 (3): 261-263. 10.3109\/10398561003686763.","journal-title":"Australas Psychiatry"},{"issue":"3","key":"1402_CR35","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.psyneuen.2005.08.010","volume":"31","author":"DL Kelly","year":"2006","unstructured":"Kelly DL, Conley RR: A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology. 2006, 31 (3): 340-10.1016\/j.psyneuen.2005.08.010.","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"1402_CR36","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4088\/JCP.v68n0206","volume":"68","author":"JM Kane","year":"2007","unstructured":"Kane JM, et al: Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry. 2007, 68 (2): 213-223. 10.4088\/JCP.v68n0206.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1402_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4088\/JCP.v68n0104","volume":"68","author":"HY Chan","year":"2007","unstructured":"Chan HY, et al: Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. J Clin Psychiatry. 2007, 68 (1): 29-36. 10.4088\/JCP.v68n0104.","journal-title":"J Clin Psychiatry"},{"issue":"1\u20132","key":"1402_CR38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.brainres.2003.09.082","volume":"1003","author":"K Aihara","year":"2004","unstructured":"Aihara K, et al: The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Res. 2004, 1003 (1\u20132): 9-17.","journal-title":"Brain Res"},{"key":"1402_CR39","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/oso\/9780192622839.003.0009","volume-title":"Sexual pharmacology","author":"TR Barnes","year":"1993","unstructured":"Barnes TR, Harvey CA: Psychiatric drugs and sexuality. Sexual pharmacology. Edited by: Riley AJ, Peet M, Wilson . 1993, Washington DC: Oxford Medical Publications, 176-196."},{"key":"1402_CR40","volume-title":"Sexual dysfunction in women using major tranquilizers","author":"K Degen","year":"1982","unstructured":"Degen K: Sexual dysfunction in women using major tranquilizers. 1982, Psychosomatics: Journal of Consultation Liaison Psychiatry"},{"issue":"Suppl 3","key":"1402_CR41","first-page":"10","volume":"61","author":"RA Dickson","year":"2000","unstructured":"Dickson RA, Seeman MV, Corenblum B: Hormonal side effects in women: typical versus atypical antipsychotic treatment. J Clin Psychiatry. 2000, 61 (Suppl 3): 10-15.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"1402_CR42","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.eurpsy.2007.01.001","volume":"22","author":"A Ucok","year":"2007","unstructured":"Ucok A, et al: Sexual dysfunction in patients with schizophrenia on antipsychotic medication. Eur Psychiatry. 2007, 22 (5): 328-333. 10.1016\/j.eurpsy.2007.01.001.","journal-title":"Eur Psychiatry"},{"issue":"2","key":"1402_CR43","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1210\/jcem-16-2-292","volume":"16","author":"WZ Polishuk","year":"1956","unstructured":"Polishuk WZ, Kulcsar S: Effects of chlorpromazine on pituitary function. J Clin Endocrinol Metab. 1956, 16 (2): 292-293. 10.1210\/jcem-16-2-292.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1402_CR44","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0165-1781(97)00137-6","volume":"77","author":"W Magharious","year":"1998","unstructured":"Magharious W, Goff DC, Amico E: Relationship of gender and menstrual status to symptoms and medication side effects in patients with schizophrenia. Psychiatry Res. 1998, 77 (3): 159-166. 10.1016\/S0165-1781(97)00137-6.","journal-title":"Psychiatry Res"},{"issue":"8","key":"1402_CR45","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/00005053-198208000-00004","volume":"170","author":"AM Ghadirian","year":"1982","unstructured":"Ghadirian AM, Chouinard G, Annable L: Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis. 1982, 170 (8): 463-467. 10.1097\/00005053-198208000-00004.","journal-title":"J Nerv Ment Dis"},{"issue":"5\u20136","key":"1402_CR46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0360-3016(76)90004-3","volume":"1","author":"JT Chaffey","year":"1976","unstructured":"Chaffey JT, et al: Total body irradiation as treatment for lymphosarcoma. Int J Radiat Oncol Biol Phys. 1976, 1 (5\u20136): 399-405.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"1402_CR47","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.4065\/72.12.1161","volume":"72","author":"B McIver","year":"1997","unstructured":"McIver B, Romanski SA, Nippoldt TB: Evaluation and management of amenorrhea. Mayo Clin Proc. 1997, 72 (12): 1161-1169. 10.4065\/72.12.1161.","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"1402_CR48","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1517\/14656566.4.12.2259","volume":"4","author":"M Gitlin","year":"2003","unstructured":"Gitlin M: Sexual dysfunction with psychotropic drugs. Expert Opin Pharmacother. 2003, 4 (12): 2259-2269. 10.1517\/14656566.4.12.2259.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"1402_CR49","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/00926230390195524","volume":"29","author":"KP Rosenberg","year":"2003","unstructured":"Rosenberg KP, et al: A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: impact on compliance. J Sex Marital Ther. 2003, 29 (4): 289-296. 10.1080\/00926230390195524.","journal-title":"J Sex Marital Ther"},{"key":"1402_CR50","first-page":"11","volume":"382","author":"WW Fleischhacker","year":"1994","unstructured":"Fleischhacker WW, et al: Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand Suppl. 1994, 382: 11-15.","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"12","key":"1402_CR51","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.4088\/JCP.v63n1206","volume":"63","author":"DO Perkins","year":"2002","unstructured":"Perkins DO: Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002, 63 (12): 1121-1128. 10.4088\/JCP.v63n1206.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"1402_CR52","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1176\/appi.ps.52.5.631","volume":"52","author":"T Burns","year":"2001","unstructured":"Burns T, et al: Case management and assertive community treatment in Europe. Psychiatr Serv. 2001, 52 (5): 631-636. 10.1176\/appi.ps.52.5.631.","journal-title":"Psychiatr Serv"},{"issue":"3","key":"1402_CR53","doi-asserted-by":"publisher","first-page":"331","DOI":"10.4088\/JCP.v66n0309","volume":"66","author":"M Olfson","year":"2005","unstructured":"Olfson M, et al: Male sexual dysfunction and quality of life in schizophrenia. J Clin Psychiatry. 2005, 66 (3): 331-338. 10.4088\/JCP.v66n0309.","journal-title":"J Clin Psychiatry"},{"issue":"3 Suppl 1","key":"1402_CR54","first-page":"S27","volume":"23","author":"S Smith","year":"2003","unstructured":"Smith S: Effects of antipsychotics on sexual and endocrine function in women: implications for clinical practice. J Clin Psychopharmacol. 2003, 23 (3 Suppl 1): S27-S32.","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl 1","key":"1402_CR55","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1097\/00004850-199702001-00005","volume":"12","author":"CA Tamminga","year":"1997","unstructured":"Tamminga CA, et al: Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Int Clin Psychopharmacol. 1997, 12 (Suppl 1): S29-S35.","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"1402_CR56","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2190\/P60R-PLED-TL09-TUEN","volume":"22","author":"MH Pollack","year":"1992","unstructured":"Pollack MH, Reiter S, Hammerness P: Genitourinary and sexual adverse effects of psychotropic medication. Int J Psychiatry Med. 1992, 22 (4): 305-327.","journal-title":"Int J Psychiatry Med"},{"issue":"4","key":"1402_CR57","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/oxfordjournals.schbul.a007130","volume":"30","author":"DL Kelly","year":"2004","unstructured":"Kelly DL, Conley RR: Sexuality and schizophrenia: a review. Schizophr Bull. 2004, 30 (4): 767-779. 10.1093\/oxfordjournals.schbul.a007130.","journal-title":"Schizophr Bull"},{"issue":"1","key":"1402_CR58","first-page":"3","volume":"48","author":"MH Pollack","year":"1987","unstructured":"Pollack MH, Rosenbaum JF: Management of antidepressant-induced side effects: a practical guide for the clinician. J Clin Psychiatry. 1987, 48 (1): 3-8.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1402_CR59","first-page":"249","volume":"7","author":"WW Shen","year":"1982","unstructured":"Shen WW, Park S: Thioridazine-induced inhibition of female orgasm. Psychiatric Journal of the University of Ottawa. 1982, 7 (4): 249-251.","journal-title":"Psychiatric Journal of the University of Ottawa"},{"issue":"6","key":"1402_CR60","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3949\/ccjm.60.6.428","volume":"60","author":"C Faiman","year":"1993","unstructured":"Faiman C: Endocrine causes of impotence. Cleve Clin J Med. 1993, 60 (6): 428-429. 10.3949\/ccjm.60.6.428.","journal-title":"Cleve Clin J Med"},{"issue":"1","key":"1402_CR61","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/0006-3223(94)91164-9","volume":"35","author":"MA Burke","year":"1994","unstructured":"Burke MA, McEvoy JP, Ritchie JC: A pilot study of a structured interview addressing sexual function in men with schizophrenia. Biol Psychiatry. 1994, 35 (1): 32-35. 10.1016\/0006-3223(94)91164-9.","journal-title":"Biol Psychiatry"},{"issue":"3","key":"1402_CR62","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/00926230701267829","volume":"33","author":"PA Nakonezny","year":"2007","unstructured":"Nakonezny PA, Byerly MJ, Rush AJ: The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine. J Sex Marital Ther. 2007, 33 (3): 203-216. 10.1080\/00926230701267829.","journal-title":"J Sex Marital Ther"},{"key":"1402_CR63","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1192\/bjp.181.1.49","volume":"181","author":"SM Smith","year":"2002","unstructured":"Smith SM, O\u2019Keane V, Murray R: Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry. 2002, 181: 49-55. 10.1192\/bjp.181.1.49.","journal-title":"Br J Psychiatry"},{"key":"1402_CR64","first-page":"285","volume":"49","author":"D Kelly","year":"2001","unstructured":"Kelly D, et al: Evaulating sexual function and prolactin levels in treatment-resistant schizophrenia. Schizophr Res. 2001, 49: 285-","journal-title":"Schizophr Res"},{"issue":"1","key":"1402_CR65","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/00004714-199902000-00011","volume":"19","author":"DL Kleinberg","year":"1999","unstructured":"Kleinberg DL, et al: Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol. 1999, 19 (1): 57-61. 10.1097\/00004714-199902000-00011.","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"1402_CR66","first-page":"1238","volume":"41","author":"G Sullivan","year":"1990","unstructured":"Sullivan G, Lukoff D: Sexual side effects of antipsychotic medication: evaluation and interventions. Hosp Community Psychiatry. 1990, 41 (11): 1238-1241.","journal-title":"Hosp Community Psychiatry"},{"issue":"3","key":"1402_CR67","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/archpsyc.1989.01810030081011","volume":"46","author":"RT Segraves","year":"1989","unstructured":"Segraves RT: Effects of psychotropic drugs on human erection and ejaculation. Arch Gen Psychiatry. 1989, 46 (3): 275-284. 10.1001\/archpsyc.1989.01810030081011.","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"1402_CR68","first-page":"22","volume":"30","author":"K DL","year":"2005","unstructured":"DL K: The schizophrenic patient: the reproductive years and beyond. The Female Patient, OB-GYN Edition. 2005, 30 (8): 22-31.","journal-title":"The Female Patient, OB-GYN Edition"},{"issue":"1","key":"1402_CR69","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0022-5347(17)66946-5","volume":"114","author":"P Moloney","year":"1975","unstructured":"Moloney P, Elliott G, Johnson H: Experiences with priapism. J Urol. 1975, 114 (1): 72-","journal-title":"J Urol"},{"key":"1402_CR70","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/NDT.S4766","volume":"5","author":"H Liu-Seifert","year":"2009","unstructured":"Liu-Seifert H, et al: Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone. Neuropsychiatr Dis Treat. 2009, 5: 47-54.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"1402_CR71","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.pnpbp.2011.11.016","volume":"37","author":"T Kikuchi","year":"2012","unstructured":"Kikuchi T, et al: Sexual dysfunction and hyperprolactinemia in Japanese schizophrenic patients taking antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2012, 37 (1): 26-32. 10.1016\/j.pnpbp.2011.11.016.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"1402_CR72","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0006-3223(95)00062-L","volume":"38","author":"G Abraham","year":"1995","unstructured":"Abraham G, et al: Osteoporosis and schizophrenia: can we limit known risk factors?. Biol Psychiatry. 1995, 38 (2): 131-132. 10.1016\/0006-3223(95)00062-L.","journal-title":"Biol Psychiatry"},{"issue":"5","key":"1402_CR73","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/0006-3223(96)82517-0","volume":"40","author":"G Abraham","year":"1996","unstructured":"Abraham G, Friedman RH, Verghese C: Osteoporosis demonstrated by dual energy x-ray absorptiometry in chronic schizophrenic patients. Biol Psychiatry. 1996, 40 (5): 430-431. 10.1016\/0006-3223(96)82517-0.","journal-title":"Biol Psychiatry"},{"key":"1402_CR74","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1192\/bjp.184.6.503","volume":"184","author":"AM Meaney","year":"2004","unstructured":"Meaney AM, et al: Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry. 2004, 184: 503-508. 10.1192\/bjp.184.6.503.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"1402_CR75","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0920-9964(01)00321-8","volume":"59","author":"G Abraham","year":"2003","unstructured":"Abraham G, et al: Bone mineral density and prolactin associations in patients with chronic schizophrenia. Schizophr Res. 2003, 59 (1): 17-18. 10.1016\/S0920-9964(01)00321-8.","journal-title":"Schizophr Res"},{"issue":"1","key":"1402_CR76","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/01.jcp.0000150223.31007.e0","volume":"25","author":"V O\u2019Keane","year":"2005","unstructured":"O\u2019Keane V, Meaney AM: Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?. J Clin Psychopharmacol. 2005, 25 (1): 26-31. 10.1097\/01.jcp.0000150223.31007.e0.","journal-title":"J Clin Psychopharmacol"},{"key":"1402_CR77","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1192\/bjp.bp.106.023671","volume":"190","author":"L Howard","year":"2007","unstructured":"Howard L, Kirkwood G, Leese M: Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry. 2007, 190: 129-134. 10.1192\/bjp.bp.106.023671.","journal-title":"Br J Psychiatry"},{"issue":"3","key":"1402_CR78","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1176\/ajp.146.3.377","volume":"146","author":"PE Yarden","year":"1989","unstructured":"Yarden PE, et al: Adverse outcome of hip fractures in older schizophrenic patients. Am J Psychiatry. 1989, 146 (3): 377-379.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"1402_CR79","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.maturitas.2006.10.003","volume":"56","author":"T Csermely","year":"2007","unstructured":"Csermely T, et al: Relationship between adolescent amenorrhea and climacteric osteoporosis. Maturitas. 2007, 56 (4): 368-374. 10.1016\/j.maturitas.2006.10.003.","journal-title":"Maturitas"},{"issue":"7","key":"1402_CR80","doi-asserted-by":"publisher","first-page":"761","DOI":"10.4088\/JCP.v64n0704","volume":"64","author":"D Becker","year":"2003","unstructured":"Becker D, et al: Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry. 2003, 64 (7): 761-766. 10.4088\/JCP.v64n0704.","journal-title":"J Clin Psychiatry"},{"issue":"1\u20133","key":"1402_CR81","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.schres.2007.01.013","volume":"93","author":"AM Meaney","year":"2007","unstructured":"Meaney AM, O\u2019Keane V: Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr Res. 2007, 93 (1\u20133): 136-143.","journal-title":"Schizophr Res"},{"issue":"7","key":"1402_CR82","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1080\/00207450290025833","volume":"112","author":"M Bilici","year":"2002","unstructured":"Bilici M, et al: Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Int J Neurosci. 2002, 112 (7): 817-828. 10.1080\/00207450290025833.","journal-title":"Int J Neurosci"},{"issue":"4","key":"1402_CR83","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1517\/14740338.2011.560112","volume":"10","author":"SM Graham","year":"2011","unstructured":"Graham SM, et al: Risk of osteoporosis and fracture incidence in patients on antipsychotic medication. Expert Opin Drug Saf. 2011, 10 (4): 575-602. 10.1517\/14740338.2011.560112.","journal-title":"Expert Opin Drug Saf"},{"issue":"22","key":"1402_CR84","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1038\/sj.onc.1201122","volume":"14","author":"P Bosse","year":"1997","unstructured":"Bosse P, et al: Multiple neuroendocrine tumours in transgenic mice induced by c-kit-SV40 T antigen fusion genes. Oncogene. 1997, 14 (22): 2661-2670. 10.1038\/sj.onc.1201122.","journal-title":"Oncogene"},{"issue":"6","key":"1402_CR85","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1592\/phco.26.6.748","volume":"26","author":"A Szarfman","year":"2006","unstructured":"Szarfman A, et al: Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy. 2006, 26 (6): 748-758. 10.1592\/phco.26.6.748.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"1402_CR86","first-page":"74","volume":"40","author":"PM Doraiswamy","year":"2007","unstructured":"Doraiswamy PM, et al: Atypical antipsychotics and pituitary neoplasms in the WHO database. Psychopharmacol Bull. 2007, 40 (1): 74-76.","journal-title":"Psychopharmacol Bull"},{"issue":"1\u20133","key":"1402_CR87","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.schres.2007.01.022","volume":"92","author":"FP MacMaster","year":"2007","unstructured":"MacMaster FP, et al: Effect of antipsychotics on pituitary gland volume in treatment-naive first-episode schizophrenia: a pilot study. Schizophr Res. 2007, 92 (1\u20133): 207-210.","journal-title":"Schizophr Res"},{"issue":"12","key":"1402_CR88","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1001\/archpsyc.59.12.1147","volume":"59","author":"PS Wang","year":"2002","unstructured":"Wang PS, et al: Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry. 2002, 59 (12): 1147-1154. 10.1001\/archpsyc.59.12.1147.","journal-title":"Arch Gen Psychiatry"},{"issue":"1\u20134","key":"1402_CR89","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000287773","volume":"40","author":"M Fava","year":"1983","unstructured":"Fava M, et al: Psychosomatic aspects of hyperprolactinemia. Psychother Psychosom. 1983, 40 (1\u20134): 257-262.","journal-title":"Psychother Psychosom"},{"issue":"6","key":"1402_CR90","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1176\/ajp.141.6.759","volume":"141","author":"R Kellner","year":"1984","unstructured":"Kellner R, et al: Hyperprolactinemia, distress, and hostility. Am J Psychiatry. 1984, 141 (6): 759-763.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1402_CR91","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1176\/ajp.142.2.242","volume":"142","author":"MT Buckman","year":"1985","unstructured":"Buckman MT, Kellner R: Reduction of distress in hyperprolactinemia with bromocriptine. Am J Psychiatry. 1985, 142 (2): 242-244.","journal-title":"Am J Psychiatry"},{"issue":"1\u20132","key":"1402_CR92","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0920-9964(02)00350-X","volume":"63","author":"DL Kelly","year":"2003","unstructured":"Kelly DL, Conley RR: Evaluating sexual function in patients with treatment-resistant schizophrenia. Schizophr Res. 2003, 63 (1\u20132): 195-196.","journal-title":"Schizophr Res"},{"key":"1402_CR93","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1089\/jwh.2006.15.1132","volume":"15","author":"K DL","year":"2006","unstructured":"DL K: Treatment considerations in women with schizophrenia. J Womens Health. 2006, 15: 1132-1140. 10.1089\/jwh.2006.15.1132.","journal-title":"J Womens Health"},{"issue":"9","key":"1402_CR94","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","volume":"164","author":"JC Shim","year":"2007","unstructured":"Shim JC, et al: Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007, 164 (9): 1404-1410. 10.1176\/appi.ajp.2007.06071075.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"1402_CR95","doi-asserted-by":"publisher","first-page":"408","DOI":"10.4088\/JCP.v63n0506","volume":"63","author":"KS Kim","year":"2002","unstructured":"Kim KS, et al: Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry. 2002, 63 (5): 408-413. 10.4088\/JCP.v63n0506.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1402_CR96","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.pnpbp.2006.02.001","volume":"30","author":"BH Lee","year":"2006","unstructured":"Lee BH, Kim YK, Park SH: Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2006, 30 (4): 714-717. 10.1016\/j.pnpbp.2006.02.001.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2\u20133","key":"1402_CR97","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.schres.2008.09.019","volume":"107","author":"MJ Byerly","year":"2009","unstructured":"Byerly MJ, et al: Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res. 2009, 107 (2\u20133): 218-222.","journal-title":"Schizophr Res"},{"issue":"1","key":"1402_CR98","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1440-1819.2010.02156.x","volume":"65","author":"CY Chen","year":"2011","unstructured":"Chen CY, et al: Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series. Psychiatry Clin Neurosci. 2011, 65 (1): 95-97. 10.1111\/j.1440-1819.2010.02156.x.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"4","key":"1402_CR99","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","volume":"166","author":"DE Casey","year":"2003","unstructured":"Casey DE, et al: Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003, 166 (4): 391-399. 10.1007\/s00213-002-1344-3.","journal-title":"Psychopharmacology (Berl)"},{"issue":"1\u20132","key":"1402_CR100","first-page":"135","volume":"25","author":"Y Kaneda","year":"2004","unstructured":"Kaneda Y, et al: Impact of a switch from typical to atypical antipsychotic drugs on quality of life and gonadal hormones in male patients with schizophrenia. Neuro Endocrinol Lett. 2004, 25 (1\u20132): 135-140.","journal-title":"Neuro Endocrinol Lett"},{"issue":"4","key":"1402_CR101","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/026988110101500408","volume":"15","author":"PM Haddad","year":"2001","unstructured":"Haddad PM, Hellewell JS, Wieck A: Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports. J Psychopharmacol. 2001, 15 (4): 293-295. 10.1177\/026988110101500408.","journal-title":"J Psychopharmacol"},{"issue":"5","key":"1402_CR102","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00737-010-0150-x","volume":"13","author":"M Kuloglu","year":"2010","unstructured":"Kuloglu M, et al: Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature. Arch Womens Ment Health. 2010, 13 (5): 443-447. 10.1007\/s00737-010-0150-x.","journal-title":"Arch Womens Ment Health"},{"key":"1402_CR103","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1192\/bjp.bp.105.019307","volume":"189","author":"RE McCue","year":"2006","unstructured":"McCue RE, et al: Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry. 2006, 189: 433-440. 10.1192\/bjp.bp.105.019307.","journal-title":"Br J Psychiatry"},{"key":"1402_CR104","doi-asserted-by":"crossref","unstructured":"Taylor D: Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia. Evidence-based Mental Health. 2007, 10 (3):","DOI":"10.1136\/ebmh.10.3.76"},{"issue":"3","key":"1402_CR105","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/JCP.0b013e318172473c","volume":"28","author":"HN Yuan","year":"2008","unstructured":"Yuan HN, et al: A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. J Clin Psychopharmacol. 2008, 28 (3): 264-370. 10.1097\/JCP.0b013e318172473c.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"1402_CR106","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1440-1819.2009.02032.x","volume":"64","author":"MS Lee","year":"2010","unstructured":"Lee MS, et al: Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study. Psychiatry Clin Neurosci. 2010, 64 (1): 19-27. 10.1111\/j.1440-1819.2009.02032.x.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"4","key":"1402_CR107","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000118184","volume":"13","author":"JB Cohn","year":"1985","unstructured":"Cohn JB, et al: Effect of bromocriptine mesylate on induced hyperprolactinemia in stabilized psychiatric outpatients undergoing neuroleptic treatment. Neuropsychobiology. 1985, 13 (4): 173-9. 10.1159\/000118184.","journal-title":"Neuropsychobiology"},{"issue":"2","key":"1402_CR108","doi-asserted-by":"publisher","first-page":"187","DOI":"10.4088\/JCP.v65n0207","volume":"65","author":"R Cavallaro","year":"2004","unstructured":"Cavallaro R, et al: Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry. 2004, 65 (2): 187-90. 10.4088\/JCP.v65n0207.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1402_CR109","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/mds.22385","volume":"24","author":"F Andersohn","year":"2009","unstructured":"Andersohn F, Garbe E: Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Mov Disord. 2009, 24 (1): 129-33. 10.1002\/mds.22385.","journal-title":"Mov Disord"},{"issue":"8","key":"1402_CR110","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1176\/appi.ajp.2012.11091432","volume":"169","author":"RR Wu","year":"2012","unstructured":"Wu RR, et al: Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2012, 169 (8): 813-21. 10.1176\/appi.ajp.2012.11091432.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1402_CR111","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/0092623X.2011.606883","volume":"38","author":"LV Nunes","year":"2012","unstructured":"Nunes LV, et al: Strategies for the treatment of antipsychotic-induced sexual dysfunction and\/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. J Sex Marital Ther. 2012, 38 (3): 281-301. 10.1080\/0092623X.2011.606883.","journal-title":"J Sex Marital Ther"},{"issue":"3","key":"1402_CR112","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1176\/appi.ajp.163.3.494","volume":"163","author":"R Gopalakrishnan","year":"2006","unstructured":"Gopalakrishnan R, et al: Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial. Am J Psychiatry. 2006, 163 (3): 494-9. 10.1176\/appi.ajp.163.3.494.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1402_CR113","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/01.pra.0000265771.47153.a0","volume":"13","author":"B Freeman","year":"2007","unstructured":"Freeman B, Levy W, Gorman JM: Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma. J Psychiatr Pract. 2007, 13 (2): 120-4. 10.1097\/01.pra.0000265771.47153.a0.","journal-title":"J Psychiatr Pract"},{"issue":"9","key":"1402_CR114","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.4088\/JCP.v65n0918f","volume":"65","author":"I Anghelescu","year":"2004","unstructured":"Anghelescu I, Wolf J: Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report. J Clin Psychiatry. 2004, 65 (9): 1286-7. 10.4088\/JCP.v65n0918f.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1402_CR115","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1176\/appi.psy.48.4.350","volume":"48","author":"CK Steinhagen","year":"2007","unstructured":"Steinhagen CK: Normalization of prolactin with aripiprazole in a patient with psychotic depression and a comorbid pituitary microadenoma. Psychosomatics. 2007, 48 (4): 350-1. 10.1176\/appi.psy.48.4.350.","journal-title":"Psychosomatics"},{"issue":"7","key":"1402_CR116","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","volume":"60","author":"SG Potkin","year":"2003","unstructured":"Potkin SG, et al: Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003, 60 (7): 681-90. 10.1001\/archpsyc.60.7.681.","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"1402_CR117","doi-asserted-by":"publisher","first-page":"763","DOI":"10.4088\/JCP.v63n0903","volume":"63","author":"JM Kane","year":"2002","unstructured":"Kane JM, et al: Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002, 63 (9): 763-71. 10.4088\/JCP.v63n0903.","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"1402_CR118","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1176\/appi.ajp.164.7.1050","volume":"164","author":"JP McEvoy","year":"2007","unstructured":"McEvoy JP, et al: Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007, 164 (7): 1050-60. 10.1176\/appi.ajp.164.7.1050.","journal-title":"Am J Psychiatry"},{"issue":"10","key":"1402_CR119","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.4088\/JCP.09m05154yel","volume":"70","author":"JM Kane","year":"2009","unstructured":"Kane JM, et al: A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry. 2009, 70 (10): 1348-57. 10.4088\/JCP.09m05154yel.","journal-title":"J Clin Psychiatry"},{"issue":"suppl","key":"1402_CR120","first-page":"307","volume":"37","author":"J D-U","year":"2011","unstructured":"D-U J, et al: Adjunctive treatment with aripiprazole for risperidone-induced amenorrhea. in International Congress on Schizophrenia Research (ICOSR). Schiz Bull. 2011, 37 (suppl): 307-","journal-title":"Schiz Bull"},{"issue":"5","key":"1402_CR121","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/JCP.0b013e3181ee832d","volume":"30","author":"N Yasui-Furukori","year":"2010","unstructured":"Yasui-Furukori N, et al: Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol. 2010, 30 (5): 596-9. 10.1097\/JCP.0b013e3181ee832d.","journal-title":"J Clin Psychopharmacol"},{"issue":"9","key":"1402_CR122","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.4088\/JCP.v65n0918d","volume":"65","author":"S Lim","year":"2004","unstructured":"Lim S, et al: Possible increased efficacy of low-dose clozapine when combined with aripiprazole. J Clin Psychiatry. 2004, 65 (9): 1284-5. 10.4088\/JCP.v65n0918d.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"1402_CR123","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/01.wnf.0000183446.58529.30","volume":"28","author":"M Ziegenbein","year":"2005","unstructured":"Ziegenbein M, Kropp S, Kuenzel HE: Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study. Clin Neuropharmacol. 2005, 28 (5): 220-4. 10.1097\/01.wnf.0000183446.58529.30.","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"1402_CR124","doi-asserted-by":"publisher","first-page":"675","DOI":"10.4088\/JCP.v67n0420d","volume":"67","author":"LA Clarke","year":"2006","unstructured":"Clarke LA, Lindenmayer JP, Kaushik S: Clozapine augmentation with aripiprazole for negative symptoms. J Clin Psychiatry. 2006, 67 (4): 675-6. 10.4088\/JCP.v67n0420d.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1402_CR125","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2165\/00044011-200626030-00001","volume":"26","author":"M Ziegenbein","year":"2006","unstructured":"Ziegenbein M, Wittmann G, Kropp S: Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation. Clin Drug Investig. 2006, 26 (3): 117-24. 10.2165\/00044011-200626030-00001.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"1402_CR126","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1600-0447.2005.00612.x","volume":"113","author":"DC Henderson","year":"2006","unstructured":"Henderson DC, et al: An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand. 2006, 113 (2): 142-7. 10.1111\/j.1600-0447.2005.00612.x.","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"1402_CR127","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/0269881106068289","volume":"21","author":"K Karunakaran","year":"2007","unstructured":"Karunakaran K, Tungaraza TE, Harborne GC: Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?. J Psychopharmacol. 2007, 21 (4): 453-6.","journal-title":"J Psychopharmacol"},{"issue":"6","key":"1402_CR128","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/01.jcp.0000246206.65411.f5","volume":"26","author":"F Abu-Tair","year":"2006","unstructured":"Abu-Tair F, Kopitz J, Bergemann N: Clozapine augmented with aripiprazole in 5 patients with schizophrenia. J Clin Psychopharmacol. 2006, 26 (6): 669-71. 10.1097\/01.jcp.0000246206.65411.f5.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"1402_CR129","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.pnpbp.2006.03.024","volume":"30","author":"FL Rocha","year":"2006","unstructured":"Rocha FL, Hara C: Benefits of combining aripiprazole to clozapine: three case reports. Prog Neuropsychopharmacol Biol Psychiatry. 2006, 30 (6): 1167-9. 10.1016\/j.pnpbp.2006.03.024.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1402_CR130","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.pnpbp.2006.09.015","volume":"31","author":"CI Mitsonis","year":"2006","unstructured":"Mitsonis CI, et al: Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: an open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2006, 31: 373-377.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"1402_CR131","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/JCP.0b013e31819a8dbe","volume":"29","author":"DC Henderson","year":"2009","unstructured":"Henderson DC, et al: Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol. 2009, 29 (2): 165-9. 10.1097\/JCP.0b013e31819a8dbe.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"1402_CR132","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/acps.12009","volume":"127","author":"X Fan","year":"2013","unstructured":"Fan X, et al: Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand. 2013, 127 (3): 217-26. 10.1111\/acps.12009.","journal-title":"Acta Psychiatr Scand"},{"issue":"Suppl 1","key":"1402_CR133","first-page":"32","volume":"69","author":"DC Henderson","year":"2008","unstructured":"Henderson DC, Doraiswamy PM: Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry. 2008, 69 (Suppl 1): 32-44.","journal-title":"J Clin Psychiatry"},{"issue":"2 Suppl","key":"1402_CR134","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/0269881107088439","volume":"22","author":"V O\u2019Keane","year":"2008","unstructured":"O\u2019Keane V: Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol. 2008, 22 (2 Suppl): 70-5. 10.1177\/0269881107088439.","journal-title":"J Psychopharmacol"},{"key":"1402_CR135","first-page":"370","volume-title":"Diagnostic criteria from DSM-IV-TR2000","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association: Diagnostic criteria from DSM-IV-TR2000. 2000, Washington, D.C: The American Psychiatric Association, 370-"},{"key":"1402_CR136","volume-title":"User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I): Clinician Version","author":"MB First","year":"1997","unstructured":"First MB, et al: User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I): Clinician Version. 1997, Washington, D.C.: American Psychiatric Press"},{"key":"1402_CR137","volume-title":"Novak\u2019s gynecology","author":"JS Berek","year":"1996","unstructured":"Berek JS, Adashi EY, Hillard PA: Novak\u2019s gynecology. 1996, Baltimore, MD: Williams & Wilkins, 159","edition":"159"},{"issue":"1","key":"1402_CR138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00926230590475206","volume":"31","author":"M Wiegel","year":"2005","unstructured":"Wiegel M, Meston C, Rosen R: The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005, 31 (1): 1-20.","journal-title":"J Sex Marital Ther"},{"issue":"1","key":"1402_CR139","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/009262300278623","volume":"26","author":"CA McGahuey","year":"2000","unstructured":"McGahuey CA, et al: The arizona sexual experience scale (ASEX): reliability and validity. J Sex Marital Ther. 2000, 26 (1): 25-40. 10.1080\/009262300278623.","journal-title":"J Sex Marital Ther"},{"issue":"4","key":"1402_CR140","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/00926230290001448","volume":"28","author":"LR Derogatis","year":"2002","unstructured":"Derogatis LR, et al: The female sexual distress scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. J Sex Marital Ther. 2002, 28 (4): 317-30. 10.1080\/00926230290001448.","journal-title":"J Sex Marital Ther"},{"issue":"79","key":"1402_CR141","first-page":"812","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE, Gorham DR: The brief psychiatric rating scale. Psychol Rep. 1962, 10 (79): 812-","journal-title":"Psychol Rep"},{"key":"1402_CR142","volume-title":"The scale for the assessment ofNegative symptoms (SANS)","author":"NC Andreasen","year":"1983","unstructured":"Andreasen NC: The scale for the assessment ofNegative symptoms (SANS). 1983, Iowa City: University of Iowa"},{"key":"1402_CR143","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1192\/S0007125000292581","volume":"22","author":"D Addington","year":"1993","unstructured":"Addington D, Addington J, Maticka-Tyndale E: Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl. 1993, 22: 39-44.","journal-title":"Br J Psychiatry Suppl"},{"key":"1402_CR144","volume-title":"ECDEU assessment manual for psychopharmacology, revised (DHEW Publication No. ADM 76\u2013338)","author":"W Guy","year":"1976","unstructured":"Guy W: ECDEU assessment manual for psychopharmacology, revised (DHEW Publication No. ADM 76\u2013338). 1976, Rockville, MD: US Department of Health and Human Services"},{"issue":"3","key":"1402_CR145","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","volume":"20","author":"C Randolph","year":"1998","unstructured":"Randolph C, et al: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998, 20 (3): 310-9. 10.1076\/jcen.20.3.310.823.","journal-title":"J Clin Exp Neuropsychol"},{"issue":"4","key":"1402_CR146","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/00005053-199404000-00001","volume":"182","author":"RW Buchanan","year":"1994","unstructured":"Buchanan RW, Carpenter WT: Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis. 1994, 182 (4): 193-204. 10.1097\/00005053-199404000-00001.","journal-title":"J Nerv Ment Dis"},{"issue":"24","key":"1402_CR147","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1097\/00007632-200012150-00008","volume":"25","author":"JE Ware","year":"2000","unstructured":"Ware JE: SF-36 health survey update. Spine (Phila Pa 1976). 2000, 25 (24): 3130-9. 10.1097\/00007632-200012150-00008.","journal-title":"Spine (Phila Pa 1976)"},{"issue":"3","key":"1402_CR148","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/schbul\/19.3.609","volume":"19","author":"AG Awad","year":"1993","unstructured":"Awad AG: Subjective response to neuroleptics in schizophrenia. Schizophr Bull. 1993, 19 (3): 609-18. 10.1093\/schbul\/19.3.609.","journal-title":"Schizophr Bull"},{"key":"1402_CR149","first-page":"170","volume-title":"Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies","year":"1984","unstructured":"Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Edited by: Dupuy HJ, Wenger NK. 1984, Le Jacq, New York, 170-183. Chapter 9"},{"key":"1402_CR150","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"GM Simpson","year":"1970","unstructured":"Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970, 212: 11-9.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"1402_CR151","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1192\/bjp.154.5.672","volume":"154","author":"TR Barnes","year":"1989","unstructured":"Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry. 1989, 154: 672-6. 10.1192\/bjp.154.5.672.","journal-title":"Br J Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-13-214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-13-214\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-13-214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:50:22Z","timestamp":1715907022000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-13-214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,22]]},"references-count":151,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1402"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-13-214","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,22]]},"article-number":"214"}}